

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

07th February, 2025

To,

**The Corporate Relationship Department
BSE Limited**

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001.

Scrip Code: 539523

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra East,
Mumbai 400 051.

Scrip Symbol: ALKEM

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI LODR Regulations”).

Dear Sir(s)/ Madam,

Pursuant to Regulation 30 of the SEBI LODR Regulations, we wish to inform you that M/s. Alkem Laboratories Limited (“**Company**”) has through a binding term sheet dated February 07, 2025, agreed to acquire 100% stake of M/s. Adroit Biomed Limited, a company incorporated in India. The transaction is proposed to be effected through a share purchase agreement to be executed between the parties and the acquisition is to be completed on or before April 1, 2025 or such other date as may be mutually agreed between the parties, subject to customary conditions to closing.

In this regard, the necessary disclosures/ information required to be submitted pursuant to Regulation 30 of SEBI LODR Regulations and Part A of Schedule III of the aforesaid regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed herewith as Annexure I.

A copy of this disclosure will be made available on the Company’s website in accordance with Regulation 30(8) of the SEBI LODR Regulations.

Request you to kindly take the same on record.

Sincerely,

For **Alkem Laboratories Limited**

Manish Narang
President – Legal, Company Secretary & Compliance Officer

Encl: a/a

Annexure I

| Particulars | Remarks |
|---|--|
| Name of the target entity, details in brief such as size, turnover etc.: | <p>(i) Name of the Target entity: M/s Adroit Biomed Limited (“Adroit”)</p> <p>(ii) Details of Target entity: Adroit is a company incorporated under the Companies Act, 1956, with CIN: U22100MH2009PLC197761, and having its registered office at Unit No F-115, 1st Floor, Kanakia Zillion, BKC Annexure, LBS/CST Road, Kurla (West), Mumbai City, Mumbai, Maharashtra, India, 400070.</p> <p>(iii) Turnover: INR 53.55 crores for financial year ended March 31, 2024.</p> |
| Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “Arms-length” | <p>The acquisition does not fall under related party transaction.</p> <p>None of the promoter / promoter group / group companies have any interest in the entity.</p> |
| Industry to which the entity being acquired belongs | Pharmaceuticals, Nutraceuticals & Cosmetics, Dermatology |
| Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) | <p>Acquisition facilitates expansion into the Dermatology & Cosmetology segment in the following manner:</p> <ul style="list-style-type: none"> <input type="checkbox"/> Expansion of the portfolio <input type="checkbox"/> Increased market reach and penetration <input type="checkbox"/> Omni Channel presence |
| Brief details of any governmental or regulatory approvals required for the acquisition | Not Applicable |
| Indicative time period for completion of the acquisition | April 01, 2025 or such other date as may be mutually agreed between the parties. |



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

| | |
|---|---|
| Nature of consideration- whether cash consideration or share swap or any other form and details of the same | Cash consideration |
| Cost of acquisition and/ or the price at which the shares are acquired; | INR 140 crores (Rupees One Hundred & Forty Crores only) payable in two tranches, subject to adjustment on account of debt & debt like items & change in normalized working capital as on closing date and other appropriate closing adjustments. |
| Percentage of shareholding / control acquired and/or number of shares acquired; | 100% Equity Share Capital |
| Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief); | <p>Brief Background: Adroit is a company incorporated under the Companies Act, 1956, with CIN: U22100MH2009PLC197761, and having its registered office at Unit No F-115, 1st Floor, Kanakia Zillion, BKC Annexure, LBS/CST Road, Kurla (West), Mumbai City, Mumbai, Maharashtra, India, 400070. It is a pharmaceutical healthcare company with focus on dermato-cosmetology.</p> <p>Date of Incorporation: December 10, 2009</p> <p>Country: India</p> <p>Turnover as on last 3 years: (Amount in INR) March 31, 2024: 53.55 crores March 31, 2023: 48.14 crores March 31, 2022: 37.77 crores</p> |